Bright Minds Biosciences (DRUG) Competitors

$86.22 +2.96 (+3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$84.16 -2.05 (-2.38%)

As of 06:40 PM Eastern

DRUG vs. NAMS, EWTX, GPCR, DNLI, and BEAM

Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include NewAmsterdam Pharma (NAMS), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), Denali Therapeutics (DNLI), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Bright Minds Biosciences compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

: 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Bright Minds Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -906.22%. NewAmsterdam Pharma's return on equity of -26.67% beat Bright Minds Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma -906.22% -26.67% -24.82%
Bright Minds Biosciences N/A -28.62% -28.08%
: In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.85 beat NewAmsterdam Pharma's score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Bright Minds Biosciences has lower revenue, but higher earnings than NewAmsterdam Pharma. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewAmsterdam Pharma $22.50M 152.69 -$203.82M -$1.73 N/A
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
: NewAmsterdam Pharma currently has a consensus price target of $48.00, indicating a potential upside of 60.64%. Bright Minds Biosciences has a consensus price target of $128.60, indicating a potential upside of 49.15%. Given NewAmsterdam Pharma's higher possible upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Bright Minds Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.83
Bright Minds Biosciences
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
: NewAmsterdam Pharma has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.35, suggesting that its stock price is 635% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-906.22%	-26.67%	-24.82%
Bright Minds Biosciences	N/A	-28.62%	-28.08%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	152.69	-$203.82M	-$1.73	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

NewAmsterdam Pharma beats Bright Minds Biosciences on 11 of the 16 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Edgewise Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

: In the previous week, Edgewise Therapeutics had 7 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 11 mentions for Edgewise Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.85 beat Edgewise Therapeutics' score of 0.69 indicating that Bright Minds Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edgewise Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
Edgewise Therapeutics N/A N/A -$167.79M -$1.63 N/A
: Bright Minds Biosciences has a beta of -5.35, indicating that its stock price is 635% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
: Bright Minds Biosciences' return on equity of -28.62% beat Edgewise Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bright Minds Biosciences N/A -28.62% -28.08%
Edgewise Therapeutics N/A -31.97% -30.46%
: Bright Minds Biosciences currently has a consensus target price of $128.60, suggesting a potential upside of 49.15%. Edgewise Therapeutics has a consensus target price of $38.13, suggesting a potential upside of 0.30%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Edgewise Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Edgewise Therapeutics
1 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

2 Strong Buy rating(s)
2.89

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.63	N/A

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-28.62%	-28.08%
Edgewise Therapeutics	N/A	-31.97%	-30.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Bright Minds Biosciences beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

: Structure Therapeutics' return on equity of -25.90% beat Bright Minds Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Structure Therapeutics N/A -25.90% -24.54%
Bright Minds Biosciences N/A -28.62% -28.08%
: In the previous week, Structure Therapeutics had 5 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 9 mentions for Structure Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.85 beat Structure Therapeutics' score of 0.75 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Structure Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Structure Therapeutics currently has a consensus target price of $109.25, suggesting a potential upside of 165.82%. Bright Minds Biosciences has a consensus target price of $128.60, suggesting a potential upside of 49.15%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Bright Minds Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Structure Therapeutics
2 Sell rating(s)
1 Hold rating(s)

13 Buy rating(s)

3 Strong Buy rating(s)
2.89
Bright Minds Biosciences
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
: Structure Therapeutics has a beta of -1.31, indicating that its share price is 231% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.35, indicating that its share price is 635% less volatile than the S&P 500.
: Structure Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Structure Therapeutics N/A N/A -$141.20M -$0.79 N/A
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
: 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.90%	-24.54%
Bright Minds Biosciences	N/A	-28.62%	-28.08%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.79	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Summary

Structure Therapeutics beats Bright Minds Biosciences on 10 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

: Bright Minds Biosciences' return on equity of -28.62% beat Denali Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Denali Therapeutics N/A -50.13% -44.20%
Bright Minds Biosciences N/A -28.62% -28.08%
: In the previous week, Denali Therapeutics had 6 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 10 mentions for Denali Therapeutics and 4 mentions for Bright Minds Biosciences. Denali Therapeutics' average media sentiment score of 0.91 beat Bright Minds Biosciences' score of 0.85 indicating that Denali Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Denali Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 84.99%. Bright Minds Biosciences has a consensus target price of $128.60, suggesting a potential upside of 49.15%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Denali Therapeutics is more favorable than Bright Minds Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
1 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.88
Bright Minds Biosciences
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
: Denali Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Bright Minds Biosciences has a beta of -5.35, indicating that its share price is 635% less volatile than the S&P 500.
: Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics N/A N/A -$512.54M -$2.97 N/A
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
: 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-50.13%	-44.20%
Bright Minds Biosciences	N/A	-28.62%	-28.08%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.97	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Summary

Denali Therapeutics beats Bright Minds Biosciences on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Beam Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

: 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Bright Minds Biosciences presently has a consensus target price of $128.60, indicating a potential upside of 49.15%. Beam Therapeutics has a consensus target price of $49.36, indicating a potential upside of 70.79%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Bright Minds Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
Beam Therapeutics
1 Sell rating(s)

3 Hold rating(s)

11 Buy rating(s)

1 Strong Buy rating(s)
2.75
: Bright Minds Biosciences has higher earnings, but lower revenue than Beam Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
Beam Therapeutics $139.74M 21.25 -$79.99M -$1.01 N/A
: Bright Minds Biosciences has a beta of -5.35, meaning that its share price is 635% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.
: In the previous week, Beam Therapeutics had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Beam Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.65 indicating that Bright Minds Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Bright Minds Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -57.24%. Bright Minds Biosciences' return on equity of -28.62% beat Beam Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bright Minds Biosciences N/A -28.62% -28.08%
Beam Therapeutics -57.24% -30.65% -23.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A
Beam Therapeutics	$139.74M	21.25	-$79.99M	-$1.01	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-28.62%	-28.08%
Beam Therapeutics	-57.24%	-30.65%	-23.73%

Summary

Beam Therapeutics beats Bright Minds Biosciences on 10 of the 16 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$838.92M	$3.40B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-44.67	38.85	29.04	28.48
Price / Sales	N/A	155.54	476.48	60.89
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	10.35	7.03	9.67	6.67
Net Income	-$8.74M	$23.62M	$3.55B	$332.64M
7 Day Performance	-3.11%	3.67%	1.70%	2.01%
1 Month Performance	20.65%	7.17%	5.62%	9.19%
1 Year Performance	176.26%	67.04%	34.42%	39.59%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	3.4126 of 5 stars	$86.22 +3.6%	$128.60 +49.2%	N/A	$838.92M	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.9157 of 5 stars	$28.72 -5.7%	$48.00 +67.2%	N/A	$3.31B	$22.50M	N/A	4	Upcoming Earnings
EWTX Edgewise Therapeutics	1.0462 of 5 stars	$30.69 +0.1%	$38.44 +25.3%	N/A	$3.30B	N/A	N/A	60	News Coverage Upcoming Earnings Insider Trade Gap Up
GPCR Structure Therapeutics	2.7731 of 5 stars	$44.87 -1.0%	$109.25 +143.5%	N/A	$3.18B	N/A	N/A	136	Upcoming Earnings
DNLI Denali Therapeutics	3.0586 of 5 stars	$20.06 +0.6%	$35.00 +74.5%	N/A	$3.18B	$330.53M	N/A	430	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. NAMS, EWTX, GPCR, DNLI, and BEAM

How does Bright Minds Biosciences compare to NewAmsterdam Pharma?

Summary

How does Bright Minds Biosciences compare to Edgewise Therapeutics?

Summary

How does Bright Minds Biosciences compare to Structure Therapeutics?

Summary

How does Bright Minds Biosciences compare to Denali Therapeutics?

Summary

How does Bright Minds Biosciences compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. NAMS, EWTX, GPCR, DNLI, and BEAM

How does Bright Minds Biosciences compare to NewAmsterdam Pharma?

Summary

How does Bright Minds Biosciences compare to Edgewise Therapeutics?

Summary

How does Bright Minds Biosciences compare to Structure Therapeutics?

Summary

How does Bright Minds Biosciences compare to Denali Therapeutics?

Summary

How does Bright Minds Biosciences compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools